MetaVia Inc. announced on April 10, 2026, that the first patient has been dosed in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1/glucagon agonist for obesity, with data expected in the fourth quarter of 2026.
Key takeaways
The first patient was dosed in Part 3 of the Phase 1 trial for DA-1726, a novel dual oxyntomodulin analog targeting GLP-1 and glucagon receptors for obesity treatment.
Part 3 consists of two 16-week titration cohorts evaluating one-step (to 48 mg) and two-step (to 64 mg) dose-escalation strategies in 40 obese, otherwise healthy adult subjects.
Previous results from the Phase 1 MAD trial showed approximately 9% weight loss at the 48 mg dose, along with reductions in waist circumference, improved glycemic control, and early signals of liver benefit.
The company believes the dual agonist approach and potential for higher therapeutic doses with improved tolerability could represent a meaningful advantage over currently marketed therapies.
Primary endpoints for the study include monitoring adverse events, serious adverse events, and treatment-emergent adverse events, with secondary endpoints assessing pharmacokinetics and metabolic measures.
Data from the Phase 1 Part 3 trial is expected in the fourth quarter of 2026, which will provide further insight into DA-1726's efficacy and tolerability profile.